162368-02-7 Usage
Chemical structure
Contains a piperidine ring, acetyl group, and a bromine atom.
Type of compound
Synthetic compound with potential biological activities.
Acetyl group
Suggests involvement in acetylation reactions in biological processes.
Bromine atom
Adds reactivity and potential for forming covalent bonds with other molecules.
Chemical modifications
Useful for chemical modifications and drug development due to bromine atom.
Pharmaceutical applications
Piperidine ring is a common structural motif in many pharmaceutical compounds.
Potential applications
May have potential applications in the development of new drugs.
Medicinal chemistry
Has potential uses in medicinal chemistry.
Building block
Can be used as a building block for chemical synthesis.
Check Digit Verification of cas no
The CAS Registry Mumber 162368-02-7 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,6,2,3,6 and 8 respectively; the second part has 2 digits, 0 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 162368-02:
(8*1)+(7*6)+(6*2)+(5*3)+(4*6)+(3*8)+(2*0)+(1*2)=127
127 % 10 = 7
So 162368-02-7 is a valid CAS Registry Number.
162368-02-7Relevant articles and documents
NOVEL GPR119 AGONIST COMPOUNDS
-
, (2017/10/26)
The present invention relates to novel compounds of formula (I), process for preparation of the same and composition comprising these compounds.
2-AMINOPYRIDINE ANALOGS AS GLUCOKINASE ACTIVATORS
-
, (2008/12/04)
Provided are compounds that are useful in the treatment and/or prevention of diseases mediated by deficient levels of glucokinase activity, such as diabetes mellitus. Also provided are methods of treating or preventing diseases and disorders characterized by underactivity of glucokinase or which can be treated by activating glucokinase.
GLUCOKINASE ACTIVATORS
-
Page/Page column 192-193, (2008/06/13)
Provided are compounds of formula I that are useful in the treatment and/or prevention of diseases mediated by deficient levels of glucokinase activity, such as diabetes mellitus. Also provided are methods of treating or preventing diseases and disorders characterized by underactivity of glucokinase or which can be treated by activating glucokinase. (Formula I) wherein R2, L, Z, Y, G and R1 are as defined in the claims.